Amyotrophic lateral sclerosis therapy with non-purine analog xanthine oxidoreductase inhibitors

2014 Fiscal Year Final Research Report

• Project/Area Number: 24500420
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Nerve anatomy/Neuropathology
• Research Institution: Tottori University
• Principal Investigator: KATO Shinsuke 鳥取大学, 医学部, 准教授 (60194817)
• Co-Investigator(Kenkyū-buntansha): KATO Masako 鳥取大学, 医学部, 助教 (80221183) ; TAKIKAWA Miki 鳥取大学, 医学部, 助教 (80724369) ; YOKOYAMA Atsushi 鳥取大学, 医学部, 助教 (90529447)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 神経変性疾患 / 筋萎縮性側索硬化症 / 経口治療薬 / キサンチン酸化還元酵素 / キサンチン酸化還元酵素阻害剤 / プリン非類似体

Outline of Final Research Achievements

The aim of this study is to develop the new therapeutic drug for amyotrophic lateral sclerosis (ALS) that is one of the intractable diseases in which there is not an effective therapy now. Non-purine analog xanthine oxidoreductase (XOR) inhibitors as the newly-developed therapeutic drug for ALS were administered orally into the ALS model mice. The results of this study were as follows: the treated ALS mice were significantly survived, and significantly improved ALS symptoms in comparison with the untreated ALS mice. Histopathologically, the treated ALS mice were well-preserved in motor neurons, compared with the untreated ALS mice. These results show that the non-purine analog XOR inhibitors are candidates for the human ALS therapeutic drug.

Free Research Field

神経病理学